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During cancer immunoediting, tumor cells with spontaneous loss of Major 
Histocompatibility Complex (MHC) class I expression tend to gradually 
increase in the tumor microenvironment by preferentially escaping from 
immune surveillance of cytotoxic T cells even though MHC class I-deficient 
tumors have been historically considered to be susceptible to NK cell-
dependent cytotoxicity. Recent studies demonstrated that most NK cells 
found in the tumor microenvironment of advanced cancers are defective, 
releasing the malignant MHC class I-deficient tumors from NK cell-
dependent immune control. Here, I showed that an NKT cell-ligand loaded 
tumor-antigen expressing APC (Antigen Presenting Cell)-based vaccine 
effectively eradicated these advanced tumors that are not curable with a single 
immunotherapy. In this process, I found that the co-expression of Tim-3 and 
PD-1 marks functionally exhausted NK cells in advanced tumors and that 
MHC class I downregulation in tumors was closely associated with the 
induction of NK cell exhaustion in tumor-bearing mice as well as in cancer 
patients. Furthermore, the recovery of NK cell function by IL-21 was critical 
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for the anti-tumor effect of the vaccine against these advanced tumors. These 
results reveal the process involved in the induction of NK-cell dysfunction in 
advanced cancers and provide a guidance for the development of strategies 
for cancer immunotherapy. 
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Introduction 
MHC class I loss or downregulated tumour cells on cancer patients 
 Although a number of anti-cancer immunotherapies are currently 
being investigated in clinical trials, one of the major obstacles in treating 
advanced cancer is that tumour cells escape host immune responses via the 
downregulation of MHC class I such as beta 2 microglobulin and heavy chain 
gene of class I  (Figure 1)1, 2. The malignant transformation and subsequent 
selection of highly metastatic cells by the immune system result in the loss of 
MHC class I in the neoplasm, contributing to tumour evasion from 
immunosurveillance by cytotoxic T lymphocytes (CTLs). Because CTLs 
cannot attack the MHC class I-deficient tumour cells. MHC class I 
downregulation or loss helps tumour cells evade the conventional CTLs 
dependent immune responses. Although It simultaneously impose another, 
the NK cell-associated immunosurveillance, activated by the ‘missing self’ 
signal, the downregulation of MHC class I in tumours induces NK cell 
dysfunction, leading to the outgrowth of MHC class I-deficient tumours 
(Figure 2)3, 4. However, the underlying mechanisms involved in the induction 
of NK cell dysfunction by MHC class I-deficient tumour cells and the best 
way to overcome the tolerogenic tumour microenvironment in advanced 
cancer remain to be elucidated 5. Early studies indicated that the activation of 
NK cells is regulated by the integration of signals derived from activating and 
inhibitory receptors expressed on the cell surface 6. In the presence of MHC 
class I on target cells, inhibitory NK cell receptors are triggered, leading to 
the inhibition of target cell lysis 7. In contrast, upon the down-regulation of 
MHC class I on target cells, signals from activating receptors take precedence 
over those from inhibitory receptors, resulting in the lysis of target cells 8. 
Paradoxically, however, MHC class I deficiency has been reported in a 
number of advanced cancers and is associated with NK cell dysfunctionality, 
which forms the basis for a long-standing question regarding cancer immune 
evasion 4, 5, 9, 10. 
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Figure 1. MHC class I downregulation or loss on tumour cells. 
(A) Immunohistochemistry of MHC class I and HLA-DR expression on 
gastro intestinal and melanoma visceral metastases2. (B) Frequencies of HLA 
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Figure 2.  MHC class I deficient tumour induce NK cell anergy  
When tumour cells lose MHC class I expression, which can occur for a variety 
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Immune exhaustion and checkpoint blockade 
Co-inhibitory receptors, such as programmed death 1 (PD-1) and T 
cell immunoglobulin and mucin domain 3 (Tim-3), play a crucial role in 
mediating T cell exhaustion in both viral infections and tumours (Figure 3)12, 
13. At first, Tim-3 and PD-1 were initially known to be activation markers of 
T cells. However, recent studies have demonstrated that Tim-3 and PD-1 co-
expression is a marker of exhausted T cells after repeated TCR stimulation 
during chronic infection or in the tumour microenvironment 13, 14.  Checkpoint 
blockade, which inhibits PD-1, Tim-3 signals, is a recent hot issue in cancer 
therapy that has shown surprising results in various cancers and infection 
patient groups 15. Recently, FDA approved immune checkpoint blockers are 
in clinical development such as monoclonal antibodies that target the PD-1, 
Tim-3 16, 17. However, Checkpoint blockaded therapy is not always effective, 
and we need a complete understanding of the specific mechanisms which 
contribute to resistance or efficacy 18. 
Currently, clinical and experimental evidence suggests that a CD8+ T 
cell, which infiltrated in tumour burden, is most favourable prognostic index 
of checkpoint blocker responses19, 20. The expression of these receptors has 
been identified in diverse immune cell populations including T cells, B cells, 
myeloid cells and macrophages21. Although previous studies demonstrated 
that the PD-1/PD-L1 and Tim-3/ligands of Tim-3 signalling down-modulated 
the cytotoxicity of NK cells against tumour cells 22, 23, their expression on NK 
cells was not well documented until a few recent human studies reported PD-
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Figure 3. Hierarchical T cell exhaustion during chronic infection.  
During initial infection, naive T cell are primed by antigen, costimulation and 
inflammation and differentiate into effector T cell. During chronic infection, 
infection persists after the effector phase. As antigen and/or viral load 
increases. T cell progress through stages of dysfunction, losing effector 
functions and other properties in a hierarchical manner.  T cell exhaustion is 
also accompanied by a progressive increase in the amount and diversity of 
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Interleukin-21 and NK cell 
Various cytokines tested in clinical trial activated NK cell and induce 
antitumor effects27. For example, IL-2, IL-12, IL-15, IL-18 and IL-21 
activates T cells and NK cells28. However, short half-life, substantial toxicity, 
poor responses in cancer patients limit their clinical admiration29. So, we need 
to understand cytokine biology in tumor microenvironments, and which 
cytokine could be more effective for eradicating tumor cells than others. IL-
21 is a cytokine mainly produced by follicular helper T cell (TFH cell), T 
helper 17 cells (TH17) and natural killer T cell (NKT cell)
30. The IL-21 
receptor (IL-21R) is expressed on NK, B, T, and dendritic cells (Figure 4) 31. 
Several studies have reported that IL-21 acts directly on viral antigen-specific 
CD8+ T cells to enhance their functional responses and to limit exhaustion 
during chronic viral infection 32, 33, 34. IL-21 promotes the maturation of NK 
cell progenitors and activates the anti-tumour effects of NK cells through the 
NKG2D pathway 35, 36. In addition, IL-21 activates cytotoxic programs in 
both CD8+ T and NK cells, thus providing potent cytotoxic effector arms 
against cancer cells 37. Based on these studies, several clinical trials are 
currently underway 30. IL-21 transduces various molecular signals such as 
STAT, PI3K and MAPK pathways31. IL-21 stimulation leads to the activation 
of STAT1, STAT3 and STAT5 on NK cells38. IL-21 enhances the 
cytotoxicity of CD8+ T cells by upregulating T-bet and IFN-γ via STAT139, 
40. In addition to STAT1 pathway, IL-21 stimulation also activate PI3K-AKT 
pathways. These pathways are known to enhance proliferation41 and 
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Figure 4. Sources of IL-21 and its cellular targets.  
IL-21 is produced by CD4+ T cell populations, with the highest production 
by TFH cells and TH17 cells, and slightly lower levels produced by natural 
killer T cells. CD8+ T cells can also produce IL-21. IL-21 exerts actions on 
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Purpose of this study 
Our laboratory have previously reported that an invariant natural 
killer T (NKT) cell ligand, alpha-galactosylceramide (αGC), loaded on a 
tumour antigen (tAg)-expressing B cell- and monocyte-based vaccine 
(B/Mo/tAg/αGC) elicited diverse anti-tumour immune responses (Figure 5) 
44, 45, 46. Initially, our study aimed to demonstrate whether B/Mo/tAg/αGC 
induces antitumor effects in MHC class I-deficient tumor-bearing hosts. 
Although recent studies have reported that MHC class I-deficient tumors 
induce NK cell dysfunction 3, 4,  
In this study, I found that B/Mo/tAg/αGC effectively eradicated 
otherwise resistant MHC class I–deficient tumour cells by activating NKT 
cells and inducing tumour antigen-specific cytotoxic T cell responses. 
Whereas MHC class I-deficient tumour cells selectively induced Tim-3+PD-
1+ NK cells with impaired cytotoxicity in the tumour microenvironment, 
B/Mo/tAg/αGC vaccination restored the cytotoxic capacity of NK cells. In 
addition, I found that the functional recovery of exhausted Tim-3+PD-1+ NK 
cells by vaccination was solely dependent on the activation of PI3K-AKT-
Foxo1 and STAT1 signalling pathways by IL-21 produced by NKT cells. 
Accordingly, the addition of recombinant IL-21 restored the function of 
intratumoural Tim-3+PD-1+ NK cells both in animal models and in human 
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Figure 5.  Mode of action of NKT ligand loaded tumour antigen 
expressing B cell and monocyte based vaccine. 
An invariant natural killer T (NKT) cell ligand, alpha-galactosylceramide 
(αGC), loaded on a tumour antigen (tAg)-expressing B cell- and monocyte-
based vaccine (B/Mo/tAg/αGC) elicited diverse anti-tumour immune 
responses such as CD4, CD8 T cell and NK cell responses and tumour antigen 
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Materials and Methods 
Mice  
Female C57BL/6 and BALB/c mice were purchased from Charles River 
Laboratories (Seoul, Korea). The Jα281−/− mice were kindly provided by Dr. 
Doo-Hyun Chung (Seoul National University, Seoul, Korea). The Rag 1−/− 
mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). 
The IFN-γ-reporter-eYFP (GREAT) mice on a C57BL/6 background were 
kindly provided by Dr. Richard M. Locksley (University of California, San 
Francisco, USA). The IL-2Rγ−/−Rag2−/− mice were purchased from Taconic 
(Germantown, New York, USA) All mice were used at 6 to 10 weeks of age 
and were bred and maintained in the specific pathogen-free vivarium of Seoul 
National University. All animal experiments were approved by the 
Institutional Animal Care and Use Committee (IACUC; SNU-130104-1-3) at 
Seoul National University. 
Human Samples 
The human tumour tissue and normal tissue specimens from patients with 
colorectal, melanoma and bladder cancer were cut into small pieces at the 
Department of Surgery, Shinchon Severance Hospital, Yonsei University 
College of Medicine.  
Human peripheral blood was obtained from healthy volunteers, and informed 
consent was granted from all donors. Peripheral blood mononuclear cells 
(PBMCs) were prepared by Ficoll-Hystopaque (Sigma-Aldrich, USA) 
density gradient centrifugation. The collection of human samples and all 
human experiments were approved by the ethical committee of Seoul 
National University and Shinchon Severance Hospital, Yonsei University 
College of Medicine (IRB No. 1309/001-023). 
Reagents and antibodies 
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The antibodies for flow cytometry and western blot assays were purchased 
from Biolegend (San Diego, CA, USA), eBioscience (San Diego, CA, USA), 
BD Bioscience (San Jose, CA, USA) and Cell Signaling Technology 
(Danvers, MA, USA). Antibody information can be found in Table 1.  All 
microbeads (CD3ε, CD11b, CD19, CD14, B220, EpCam and Biotin) for 
lymphocyte depletion or selection were purchased from Miltenyi Biotec 
(Bergish Galdbach, Germany). The antibodies for in vivo depletion (Asialo 
GM-1, NK1.1 (PK136), CD4 (GK1.5), CD8 (2.43), IL-21R (4A9) and IFN-γ 
(XMG 1.2)), were prepared in the laboratory or purchased from Biolegend or 
BioXcell. The recombinant mouse IL-2, mouse IL-21, human IL-2, human 
IL-21, ULBP2 and human NKp46 antibodies were purchased from R&D 
Systems. Chemical inhibitors, including S31-201, Fludarabine, LY294002, 
and PD98059, were purchased from Selleckchem (Houston, TX, USA) 
Cell line generation and culture 
The TC-1, CT26, MC38, K562 and HeLa cells were purchased from ATCC. 
The cells were cultured in DMEM or IMEM (GIBCO) supplemented with 10% 
FBS (GIBCO) and 1% penicillin-streptomycin. The optimized sgRNA 
constructs, targeting H-2Kb (Exon 3: AGCCGTCGTAGGCGTACTGCTGG), 
H-2Db (Exon 3: AGTCACAGCCAGACATCTGC TGG), mouse Beta 2 
microglobulin (Exon 2: TCACGCCACCCACCGGAGAATGG) and human 
Beta 2 microglobulin (Exon 1: GAGTAGCGCGAGCACAGCTAAGG), and 
the Cas9 expression construct, pRGEN-Cas9-CMV, were obtained from 
ToolGen (Seoul, Korea). The TC-1 H-2Kb,Db, MC38 H-2Kb,Db, CT26 Beta 
2 microglobulin and HeLa Beta 2 microglobulin knock out cell lines were 
generated by transfection with the indicated sgRNA construct and pRGEN-
Cas9-CMV using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s protocol. MHC class I-deficient cells were sorted by a T7E1 
assay with single cell selection or with a FACSARIA III (BD Bioscience). 
For primary cell cultures, mouse primary cells were cultured in RPMI 
(GIBCO) medium supplemented with 10% FBS (GIBCO) and 1% penicillin-
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streptomycin (Lonza). Human primary cells were cultured in X-VIVO15 
medium (Lonza) that was supplemented with 1% penicillin-streptomycin 
(Lonza). For NK cell culture, a low dose (1~2 ng/ml) of rIL-2 was added to 
the culture medium for cell survival. All cell lines were found to be negative 
for mycoplasma contamination. 
Construction of recombinant adenoviruses 
All adenoviral vectors were constructed by Cellid, Inc. (Seoul, Korea). To 
construct the adenoviral vector that expressed the HPV antigen E6/E7 gene 
in the E1 region of adenovirus, we first constructed a pShuttle-CMV vector 
(Agilent Technologies, CA, USA) that expressed the HPV antigen E6/E7 
protein. The newly generated pShuttle-CMV-E6E7 vector was co-
transformed with the pAdeasy-1 adenovirus vector (Agilent Technologies, 
CA, USA) in which a portion of the Ad type 5 fibre was replaced by a portion 
of the Ad type 35 fibre (Adk35), yielding the plasmid pAdk35-E6E7. This 
recombinant plasmid was transfected into human embryonic kidney 293 cells 
to generate the Adk35-E6E7 adenovirus.  
B/MoAdk35-E6E7/αGC and B/Mo/αGC preparation 
Splenocytes were isolated from C57BL/6 or BALB/c mice. The granulocytes 
and RBCs were removed by Ficoll (Sigma-Aldrich) density gradient 
centrifugation. After the depletion of CD3ε+ and DX5+ cells from the cell 
population using anti-mouse CD3ε and anti-mouse DX5 microbeads, the 
CD11b+ cells and B220+ cells were purified using anti-mouse CD11b and 
anti-mouse B220 microbeads (all from Miltenyi Biotec). Isolated B cells and 
monocytes (1:1 ratio mixture) were transduced with the adenoviral vector in 
a 90-min, 2800-rpm centrifugation step at room temperature, and the cells 
were subsequently incubated for an additional 18 h (for the B/Mo/αGC 
preparation this step was skipped). αGC (KRN7000, Enzo Life Science, Japan) 
was loaded into the prepared B cells and monocytes for NKT activation based 
on our laboratory previous studies 44, 45, 46, 47.  
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Transplant tumour and therapeutic tumour models 
Conventional subcutaneous indicated tumours were generated by s.c. 
injection in the right flank. Tumour growth was measured using a metric 
calliper 2-3 times a week. In some experiments, tumour cells were injected 
s.c. in the flank after being resuspended in Matrigel with reduced matrix 
growth factor (BD Bioscience). For the therapeutic tumour model, 1x104-
1x106 of the indicated tumour cells were subcutaneously injected into the left 
flanks of the mice on day 0. After the randomized and blinded allocation of 
all tumour-bearing mice, the indicated vaccine or cytokine was administered 
at various time points. For the TC-1 lung metastasis model, 1x105 cells were 
injected i.v. into the tail vein after resuspension in 100 μl PBS. Tumour 
formation was monitored using IVIS Spectrum microCT and Living Image 
(ver. 4.2) software (PerkinElmer, Cambridge, UK). An MMPSense 680 probe 
(PerkinElmer; 2 nmol per 150 ml in PBS) was used to facilitate tumour 
monitoring. For adoptive transfer into the IL-2Rγ−/−Rag2−/− mice, tumour 
cells were subcutaneously injected into the left flank of the mice, and on the 
next day, the indicated cells were transferred by i.v. injection into the tail vein. 
In addition, the transferred groups of No treatment, Tim-3− PD-1− NK cells 
and IL-21-treated Tim-3+ PD-1+eYFP− NK cells were injected daily with rIL-
21 (2 µg) via i.p. for 4 days. To deplete NK1.1+, CD4+, CD8+ cells, 300 μg of 
GK1.5, 2.43, PK136 or control antibodies were injected i.p. twice weekly into 
the mice the day before tumour implantation. To block IL-21R or IFN-γ, anti-
IFN-γ (500 μg/mouse) or anti-IL-21R (300 μg/mouse) or both were injected 
i.p. nine days after tumour implantation, and two days later, the indicated 
cellular vaccine was injected along with the neutralizing antibodies. 
Antibody staining and flow cytometry analysis 
Dead cells were excluded by staining with Fixable Viability Dye (eBioscience, 
CA, USA) following the manufacturer’s instruction. The cells were stained 
with the specified antibodies in 50 μl of FACS buffer (PBSN+1% FBS). 
Intracellular staining for cytokines was performed after surface staining with 
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the Cytofix/Cytoperm kit (BD Bioscience). For transcription factor staining, 
the Foxp3/Transcription factor staining buffer set (eBioscience) was used. In 
addition, for the intracellular staining of p-ERK, p-AKT, p-FOXO1, pSTAT1 
and pSTAT3, the cells were fixed with IC fixation buffer and permeabilized 
with 1 ml ice-cold 90% methanol on ice for at least 30 minutes in the dark 
after surface staining. The samples were acquired with a FACSCalibur or 
FACSARIA III instrument (BD Bioscience), and the data were analysed with 
Flow Jo software (Three Star). 
Tumour-infiltrating lymphocyte preparation 
Tumours were dissociated using the gentleMACS Dissociator (Miltenyi 
Biotec). The dissociated tumour samples were further digested in 10% FBS 
with RPMI medium containing 300 μg/ml collagenase D (Roche), 20 μg/ml 
hyaluronidase (Sigma Aldrich) and 20 μg/ml DNase I (Sigma Aldrich). After 
filtering through a 40-μm nylon mesh, single cell suspensions were counted 
and used for the experiments. 
In vitro cytotoxicity assay 
Effector CD8+ cells were prepared from vaccinated mouse splenocytes and 
stimulated with the E641-50 [EVYDFARDL]/E749-57 [RAHYNIVTF] peptide 
mixture for 5 days. After the 5-day stimulation, CD8+ T cells were isolated 
using anti-mouse CD8 microbeads (Miltenyi Biotec) and cocultured with 
51Cr-labeled TC-1 tumour cells for 4 hours. The CTL activity was calculated 
by the release of 51Cr in the culture supernatants through the specific lysis of 
TC-1 target cells, as measured by a Wallac 1480 Wizard automatic γ-counter 
(PerkinElmer). NK cells were prepared from vaccinated mouse splenocytes 
or infiltrating lymphocytes from MHC class I-deficient tumour-bearing mice 
or human infiltrating NK cells from cancer patients by FACSARIA II or 
FACSARIA III sorting. Next, various numbers of NK cells were cocultured 
with 51Cr-labeled TC-1 H-2Kb,Db KO cells or K562 cells. The NK cell 
cytotoxicity was calculated by 51Cr release in the culture supernatants 
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through the specific lysis of TC-1 H-2Kb,Db KO target cells or K562 cells, as 
measured by a Wallac 1480 Wizard automatic γ-counter (PerkinElmer). To 
assay the cytokine release from NK cells, 3x104~1x106 cells were stimulated 
in flat-bottomed, high protein-binding plates (Corning) that were coated with 
anti NK1.1, ULBP-2 Fc protein or hNKp46 antibodies for 5 h in the presence 
of 1 μg/ml GolgiPlug (BD) before staining the cells for intracellular IFN-γ, 
perforin or granzyme B. In some experiments, CD107a was added during cell 
stimulation. When NK cells were cocultured with tumour cells, the tumour 
cells were irradiated (5000 rads) using a gamma irradiator (GC 3000 Elan) at 
the National Center for Inter-university Research Facilities (NCIRF) at Seoul 
National University.  
Immunoblot analysis 
The cytoplasmic fractions of cells were prepared as follows: cells were 
washed once with ice-cold phosphate-buffered saline (PBS) and collected by 
centrifugation at 3,000 rpm for 5 min. The cells were resuspended in 10 mM 
HEPES, pH 7.9, 10 mM KCl, 0.2 mM EDTA, 1 mM DTT, 0.25 mM PMSF, 
and proteinase inhibitor cocktail. After incubation on ice for 5 min, NP-40 
was added to a final concentration of 0.25%. The mixtures were vortexed at 
high speed for 10 seconds. The extracts were collected by centrifugation at 
13,000 rpm for 1 minute. The supernatants were collected as cytoplasmic 
extracts.  
Immunohistochemistry 
Tumour tissues were fixed in 4% paraformaldehyde; paraffin-embedded 
tissue sections (4 mm) were deparaffinized, dehydrated, and treated with 3% 
hydrogen peroxide to block endogenous peroxidase. Slides were incubated 
with the primary antibody (Anti-MHC class 1 H-2 Db antibody, Abcam Inc, 
MA, USA). Slides were then washed with phosphate buffered saline (PBS), 
incubated with HRP secondary antibody, and washed again in PBS; colour 
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was developed using the AEC substrate. The slides were counterstained with 
haematoxylin. 
Enzyme-linked immunosorbent assay 
The following cytokines were measured in mouse serum using an ELISA kit 
according to the manufacturer’s instructions: IL-21 (eBioscience), IFN-γ, 
TNF-α and IL-4 (BD Bioscience, San Jose, CA, USA). 
Statistics 
Statistical comparisons were performed using the Prism 6.0 software 
(GraphPad Software).  
two-tailed unpaired Student’s t test: Figure 13, 15, 16A, 17A-C, 18C, 20B-C, 
21A, 24A-B, 27, 32B-G, 33A, 34B-C and 35A-B,  
two-way ANOVA with Bonferroni multiple comparison tests: Figure 6A-C, 
7A, 11A-F, 12A,  21B, 22B, 26A, 26C, 28B, 29A-C, 30A-D, 31B, 35B and 
36 















Effects of the vaccine for advanced tumours 
To investigate whether B/Mo/tAg/αGC has anti-tumour effects on 
large established tumours, I first developed a B/Mo/tAg/αGC vaccine 
expressing the E6/E7 tumour Ag of human papillomavirus-associated cancer 
(B/Mo/E6E7/αGC). I found that B/Mo/E6E7/αGC elicited activation of NKT 
(Figure 6A) and NK cells (Figure 6B) and induced antigen-specific CTL 
responses (Figure 6C). A single vaccination on day 7 with B/Mo/E6E7/αGC 
was successful for the treatment of mice bearing small E6/E7-expressing TC-
1 tumours (Figure 7A) and protected mice against tumour re-growth (Figure 
8). Multiple vaccinations at late time points effectively eradicated large 
established TC-1 tumours (Figure 7B), and lung metastases derived from TC-
1 tumour cells were efficiently eradicated by vaccination with 
B/Mo/E6E7/αGC (Figure 7C-D). To investigate the effects of 
B/Mo/E6E7/αGC on MHC class I-downregulated tumours, I analysed the 
kinetics of H-2Kb and H-2Db expression on tumours. A gradual 
downregulation of H-2Kb and H-2Db was observed with tumour progression 
(Figure 9A-B). The cytotoxic activity of NK cells gradually increased during 
tumour progression, while the cytotoxicity of CD8+ T cells gradually 
decreased (Figure 9C-D). The cytotoxicity of NK cells was inversely 
correlated with the expression of H-2Kb, Db on tumours, whereas that of CD8+ 
T cells was positively correlated with the expression of H-2Kb, Db (Figure 
9E). This observation prompted us to address whether MHC class I-
deficiency can affect NK cell functions 9. To this end, I established H-2Kb, 
Db-deficient or beta2-microglobulin (β2m)-deficient tumours (Figure 10A-B). 
The progression of tumour growth in the respective syngeneic mice was 
comparable between WT and MHC class I-deficient tumours (Figure 10C-
E).  
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Figure 6. NKT ligand-loaded tumour antigen-presenting B cell- and 
monocyte-based vaccine induces NKT, NK and CD8 T cell responses. 
(A) The cytokine profiles of liver iNKT cells were assessed in B/Mo/Adk35-
E6E7/αGC-injected mice at various times. The levels of IL-4 and IFN-γ were 
detected by flow cytometry. (B) Twelve days after TC-1 WT cell implantation, 
IFN-γ production by tumour-infiltrating NK cells was assessed in B/Mo-, 
B/Mo/Adk35-E6E7- and B/Mo/Adk35-E6E7/αGC-injected mice. (C) 
C57BL/6 mice were vaccinated with the indicated form of B/Mo. One week 
later, in vivo CTL assays were performed by injecting CFSE-labelled 
syngeneic targets. CFSEhigh, peptide pulsed target; CFSElow, peptide unpulsed 
control. In vitro assays were performed using vaccinated mice splenocytes 
that were restimulated with the HPV16 E6/E7 peptide mixture (E6: 
EVYDAFRDL, E7: RAHYNIVTF), and cytotoxicity against TC-1 cells was 
measured using a standard 51Cr release assay. The data shown are from at 
least 2 individual experiments with similar results. The data in A, B and C 
were analysed by two-way ANOVA with Bonferroni multiple comparison 
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Figure 7. Anti-tumour effects of BVAC-C. (A) Each group of mice (n=6) 
was vaccinated with the indicated cellular vaccine at day 6 after TC-1 tumour 
s.c. injection (1x105) at day 0. (B) Each group of mice (n=8) was vaccinated 
with the indicated cellular vaccine at day 10, 24 and 41 after TC-1 tumour s.c. 
injection (5x105) at day 0. The tumour size was measured three times weekly. 
(C-D) Each group of mice (n=10) was vaccinated with the indicated cellular 
vaccine at day 7, 14 and 21 after TC-1 tumour i.v. injection (1x105) at day 0. 
(D) In vivo imaging of TC-1 metastatic mice (day 40) treated with 
metalloproteinase. The data in A were analysed by two-way ANOVA with 
Bonferroni multiple comparison tests. The data in C were analysed using a 
log-rank (Mantel-Cox) test (conservative) *P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001. The data are representative of three independent experiments 
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Figure 8. Memory anti-tumour responses induced by vaccination. 
Tumour-free mice from Fig. 7A and naïve mice (n=6) were vaccinated with 
the indicated cellular vaccine at day 6 after TC-1 tumour s.c. rechallenge 
(1x105) on the opposite flank as on day 0. The data shown are from at least 2 
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Figure 9. MHC class I downregulation affects anti-tumour immunity. (A) 
Expression of H-2Kb, Db on tumours. C57BL/6 mice were implanted in the 
flank with 1x105 TC-1 cells (Day 0 indicates in vitro cultured tumour cells). 
(B) H-2Kb, Db expression (E) is shown with tumour size. (C-D) Each graph 
depicts the specific lysis of extracted TC-1 cells at different time points. CD8+ 
T cells and NK cells were isolated from the spleens of B/Mo/ E6E7/αGC-
immunized mice at day 1 and 7 as effector cells. (E) The data presented in G-
H reassembled with the H-2Kb, Db level on tumours and the percentage of 
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 Figure 10. H-2Db, Kb or Beta 2 microglobulin knock out tumour cells. 
(A) The expression levels of H-2Db and H-2Kb on TC-1 WT or TC-1 H-
2Kb,Db KO cells were measured by flow cytometry. (B) The H-2Db 
expression level in TC-1 WT or TC-1 H-2Kb,Db KO-bearing mouse tumour 
(n=5) sections was detected by immunohistochemistry (H2-Db: brown, 
tumour: blue, Scale bar: 100μm). (C-E) The tumour size was measured after 
s.c. implantation of the indicated tumour cells. The data shown are from at 
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Anti-tumour effects of B/Mo/αGC on MHC class I-deficient tumours 
Several mouse and human studies have shown that NKT cell 
activation triggers anti-tumour immune responses by enhancing NK cell 
activation 48, 49. To verify that this was also the case with MHC class I-
deficient tumours, mice were injected with αGC-loaded B cells and 
monocytes (B/Mo/αGC) followed by MHC class I-deficient tumour 
inoculation. The B/Mo/αGC administration resulted in a significant reduction 
in the growth of MHC class I-deficient tumours compared with B/Mo (Figure 
11A-C). I also found that treatment with anti-NK1.1 or anti-asialo GM1 
significantly reversed the inhibition of tumour growth, which indicated that 
the anti-tumour immunity was dependent on NK and NKT cells (Figure 11D-
F). However, human malignant primary tumours are well known for their 
heterogeneous MHC class I expression levels 2, 11. Therefore, I hypothesized 
that NKT cell ligand-loaded tumour antigen-expressing vaccination can 
eradicate both MHC class I-sufficient and MHC class I-deficient tumour cells 
by inducing adaptive and innate immune responses. MHC class I-sufficient 
tumours could be eradicated by adaptive immune responses, such as CD8+ T 
cells, and MHC class I-deficient tumours could be eradicated by innate 
immune responses, such as the response of NK cells. To address this 
hypothesis, I established a heterogeneous tumour model in which a mixture 
of MHC class I sufficient- and MHC class I-deficient tumour cells was 
inoculated at different ratios. The data revealed that the vaccine regimen 
induced complete tumour eradication and a long-lasting cure in 90% of the 
mice bearing heterogeneous tumours and thus contain up to 10% MHC class 
I-deficient TC-1 tumour cells (Figure 12A-B). B/Mo/E6E7/αGC 
administration induced robust tumour eradication and durable cures in >70% 
of the mice bearing heterogeneous tumours, which contained 20% MHC class 
I-deficient TC-1 tumour cells. In contrast, B/Mo/E6E7 or B/Mo/αGC 
administration elicited weaker anti-tumour responses and reduced survival 
rates (Figure 12C). Antibody depletion experiments showed that CD8+ T and 
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NK cells were crucial for heterogenic tumour eradication and led to 
reductions in the survival rates (Figure 12D). These results indicate that the 
vaccine regimen is effective against the heterogeneous tumours by inducing 
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Figure 11. Eradication of MHC class I deficient tumour by NK and NKT 
dependent manner. (A-C) Subcutaneous growth of WT and MHC class I 
KO tumour cells (TC-1, MC38: H-2Kb, Db KO, CT26: β2m KO) in each 
group of mice (n=6) treated with B/Mo (1x106), B/Mo/αGC (1x106) and αGC 
(1 μg) every 7 days. (D-F) Subcutaneous growth of the indicated tumour cells 
in each group of mice (n=6) treated with B/Mo (1x106) or B/Mo/αGC (1x106) 
every week. The tumour bearing mice were treated control IgG, anti-NK1.1 
(PK136) or anti-asialo GM-1 to deplete NK cells on day 36 (TC-1) or day 12 
(MC38 and CT26). A-F were analysed by a two-way ANOVA with 
Bonferroni multiple comparison tests. *P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001. The data are representative of three independent experiments 
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Figure 12. Eradication of heterogeneous tumours by induced adaptive 
and innate immune responses. (A-B) Each group of mice (n=10) was 
vaccinated with the indicated cellular vaccine every 7 days after s.c. injection 
of the indicated mixed (WT and MHC class I-deficient tumour) or solid (TC-
1) tumours (1x105) at day 0. (C-D) Survival over time with depleting 
antibodies for indicated cells (PK136 for NK cells depletion, 2.43 for CD8+ 
T cell depletion and GK1.5 for CD4+ T cell depletion) administered i.p.1d 
before initiation of the vaccination. Each group of mice (n=12) was 
vaccinated with the indicated cellular vaccine every 7 days after s.c. injection 
of the mixed (TC-1 WT and MHC class I-deficient tumour ratio = 80:20) 
tumours (1x105) at day 0. A were analysed by a two-way ANOVA with 
Bonferroni multiple comparison tests. The data in B-D were analysed by a 
log-rank (Mantel-Cox) test (conservative) *P<0.05, **P<0.01, ***P<0.001, 
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MHC I deficient tumours induce Tim-3 and PD-1 on NK cells 
Although recent studies have demonstrated that MHC class I-
downregulation or deficiency in tumour cells induces NK cell anergy, NKT 
cell ligand-loaded APC-based tumour Ag-expressing vaccination efficiently 
induced the eradication of tumours containing MHC class I-deficient cells. 
From this perspective, I hypothesized that NK anergy in mice bearing MHC 
class I-deficient tumours might have been restored by the vaccination. To 
investigate this possibility, I analysed the cell surface marker expression 
pattern and cytotoxic function of NK cells in MHC class I-deficient tumour 
microenvironments. Recent studies have suggested that Tim-3 expression is 
a marker of NK cell activation or exhaustion 23, 24. I observed that Tim-3 
expression on tumour-infiltrating NK cells was dramatically accelerated in 
mice bearing H-2Kb,Db-deficient tumours compared with WT tumour-
bearing mice, and most Tim-3+ NK cells co-expressed PD-1 (Figure 13). The 
levels of Tim-3 and PD-1 expression on NK cells in the spleen were very low, 
regardless of the MHC class I expression on tumours, but those in tumour-
draining lymph nodes were slightly increased in mice bearing H-2Kb, Db-
deficient tumours compared with WT tumour-bearing mice, although this 
increase was not statistically significant (Figure 14). The expression levels 
of NK cell-activating receptors, including Ly49D, DNAM-1, CD69, and 
CD160, were significantly higher in Tim-3+ PD-1+ NK cells compared with 
Tim-3−PD-1− cells. The expression of NK cell-inhibitory receptors such as 
NKG2A/C/E, KLRG1, TIGIT and 2B4 was comparable between the groups, 
but Ly49A was downregulated in Tim-3+PD-1+ NK cells (Figure 15). To 
investigate whether the tumours could directly induce the expression of Tim-
3 and PD-1 on NK cells, I cocultured purified NK cells with tumour cells. 
When NK cells were cocultured with WT tumour cells, Tim-3 was slightly 
induced starting on day 1, and PD-1 was not induced until day 5. However, 
when NK cells were cocultured with MHC class I-deficient tumour cells, 
Tim-3 was highly induced starting on day 1, and PD-1 was induced on day 5 
(Figure 16A). To analyse whether soluble factors produced by tumours could 
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induce Tim-3 and PD-1, NK cells were both cocultured with MHC class I-
deficient tumour cells using a transwell system and in tumour-conditioned 
medium. The expression of Tim-3 and PD-1 on NK cells was induced when 
the NK cells and MHC class I-deficient tumours were directly cocultured 
(Figure 16B). In human NK cells, Tim-3 expression was rapidly upregulated 
upon coculture with β2m-deficient HeLa cells compared with NK cells 
cocultured with WT HeLa cells (Figure 17A). Human NK cell-activating 
receptors, including NKG2D, DNAM-1 and CD69, and the inhibitory 
receptor 2B4 were significantly upregulated on Tim-3+ NK cells compared to 
Tim-3− cells. However, expression of the inhibitory receptor KLRG1 was 
significantly downregulated in Tim-3+ NK cells (Figure 17B). The levels of 
PD-1 on Tim-3+ NK cells were slightly higher than those on Tim-3− cells 
(Figure 17C). These results collectively suggest that Tim-3+PD-1+ NK cells 
express higher levels of activating receptors. 
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Figure 13. Natural killer cells in MHC class I-deficient tumours exhibit 
accelerated Tim-3 and PD-1 expression.  The kinetic expression levels of 
Tim-3 and PD-1 on tumour-infiltrating natural killer cells from TC-1 WT or 
H-2Kb,Db KO tumour-bearing mice (n=5) were analysed by flow cytometry. 
The data in A were analysed by a two-tailed unpaired Student’s t test. *P<0.05, 
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Figure 14. Tim-3 and PD-1 expression on natural killer cells in the 
indicated organs. The kinetic expression levels of Tim-3 and PD-1 on natural 
killer cells from TC-1 WT or H-2Kb,Db KO tumour-bearing mice (n=5) were 
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Figure 15. Various inhibitory and activation molecule expression on 
indicated NK cells. Tim-3+PD-1+ or Tim-3−PD-1− NK cells from TC-1 H-
2Kb,Db KO tumours were stained with antibodies for the activating receptors 
Ly49D, DNAM-1, CD69 and CD160 or the inhibitory receptors NKG2A/C/E, 
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Figure 16. Tim-3 and PD-1 expression on NK cells in vitro. (A) The daily 
kinetic Tim-3 and PD-1 expression levels on NK cells were analysed after 
MC38 WT or H-2Kb,Db KO tumour cells were cocultured in vitro with splenic 
NK cells from C57BL/6 mice. (B) The expression levels of Tim-3 and PD-1 
on NK cells were assessed after coculture with TC-1 H-2Kb,Db KO cells via 
transwell or the addition of tumour-conditioned medium. The data were 
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Figure 17. Human Natural killer cells in MHC class I-deficient tumours 
exhibit accelerated Tim-3 and PD-1 expression. (A) The Tim-3 expression 
level on human NK cells was analysed after CD16+CD56dim human NK cells 
(n=6) were cocultured with HeLa WT or β2m KO cells. (B) Tim-3+ or Tim-
3− human NK cells (n=8) cocultured with HeLa β2m KO cells for 3 days were 
stained with antibodies for the activating receptors NKG2D, DNAM-1, CD69 
and CD160 or the inhibitory receptors TIGIT, KLRG1, 2B4 and PD-1 (C). 
The data in A, B and C were analysed by a two-tailed unpaired Student’s t 
test. *P<0.05, **P<0.01, ***P<0.001. The data are representative of three 
independent experiments that included six to eight human PBMC samples. 
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Tim-3+ PD-1+ NK cells are functionally exhausted in tumour. 
Although Tim-3 and PD-1 were initially suggested to be activation 
markers of T cells, recent studies have demonstrated that Tim-3 and PD-1 co-
expression is a marker of exhausted T cells after repeated TCR stimulation 
during chronic infection or in the cancer microenvironment 13, 14. To 
investigate whether Tim-3+ PD-1+ NK cells induced by MHC class I-deficient 
tumours represent activated or exhausted NK cells, I analysed the effector 
functions of NK cell populations isolated from mice bearing WT or H-2Kb, 
Db-deficient tumours. I determined that the frequency of IFN-γ+ NK cells was 
remarkably decreased in tumour-infiltrating lymphocytes (TILs) and tumour-
draining lymph nodes (TdLNs) of mice bearing H-2Kb, Db-deficient tumours 
compared with those bearing WT tumours (Figure 18C), although the 
frequency and number of NK cells were comparable between the two groups 
(Figure 18A-B). ERK1/2 kinase is a crucial factor for the induction of 
cytokine production and cytotoxicity in NK cells 50. The levels of phospho-
ERK1/2 were significantly reduced in TIL NK cells from MHC class I-
deficient tumour-bearing mice compared with TIL NK cells from WT 
tumour-bearing mice (Figure 19A).  
To investigate the interrelationship between Tim-3 and PD-1 
expression and function on NK cells, I analysed the kinetics of the expression 
of these receptors and the IFN-γ secretion of intratumoural NK cells from 
mice bearing WT and H-2Kb, Db-deficient tumours. In mice bearing WT 
tumours, the expression of Tim-3 and PD-1 on intratumoural NK cells 
reached 50% at 28 days after tumour injection. In contrast, Tim-3 and PD-1 
were expressed much more rapidly on intratumoural NK cells from mice 
bearing H-2Kb, Db-deficient tumours than on intratumoural NK cells from 
mice bearing WT tumours, reaching up to 70% at 28 days after tumour 
injection. I also observed that IFN-γ production of intratumoural NK cells 
from both groups of mice sharply decreased in response to the increased 
expression of Tim-3 and PD-1 (Figure 20A). Of note, among the NK cells 
isolated from MHC class I-deficient tumours, Tim-3+ PD-1+ NK cells 
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exhibited a dramatically reduced expression of effector molecules such as 
IFN-γ, CD107a, granzyme B and perforin compared with their Tim-3−PD-1− 
counterparts (Figure 20B). These results suggest that when NK cells are 
stimulated, Tim-3 and PD-1 are first expressed on NK cells as an activation 
signature. However, after persistent stimulation in the absence of MHC class 
I, Tim-3+ PD-1+ expression represented the exhausted NK cell population. In 
addition, T-bet expression on Tim-3+PD-1+ NK cells in H-2Kb,Db-deficient 
tumours was also reduced compared with Tim-3−PD-1− NK cells, whereas the 
expression of Eomes was somewhat increased on Tim-3+PD-1+ NK cells 
(Figure 20C). Moreover, ERK1/2 phosphorylation was significantly 
decreased in Tim-3+PD-1+ NK cells (Figure 21A). Consistent with their 
exhausted phenotype, the cytotoxicity of the Tim-3+PD-1+ NK cells against 
H-2Kb,Db-deficient TC-1 tumours was much lower than the cytotoxicity 
exhibited by Tim-3− PD-1− NK cells (Figure 21B). I also found that Tim-
3+PD-1+ intratumoural NK cells in WT tumour-bearing mice had a similar 
exhausted phenotype, in accordance with the spontaneous downregulation of 
MHC class I on WT tumour cells (Figure 19B).  
To determine whether the PD-1/PD-L1 axis transmits negative signals 
on NK cells, I examined whether the tumour cells expressed PD-L1. My data 
showed that MC38 tumour cells had a high expression level of the PD-L1 
molecule on their surface (Figure 22A). To examine the effect of anti-PD-1 
antibody on exhausted NK cells, I treated MC38 H-2Kb, Db KO tumour-
bearing mice, which were depleted of CD8+ T cells by 2.43 mAb, with the 
anti-PD-1 antibody. This treatment significantly suppressed tumour growth 
in mice bearing MC38 H-2Kb, Db KO tumours (Figure 22B). Collectively, 
my data suggest that the PD-1/PD-L1 axis transmits negative signals on NK 
cells and that blocking the PD-1 signal could restore the anti-tumour effects 
of exhausted NK cells. When human NK cells were cocultured with β2m-
deficient HeLa cells, the IFN-γ and granzyme B levels in Tim-3+ NK cells 
were gradually decreased after restimulation with the NKG2D ligand ULBP-
2 (Figure 23A). A gradual reduction in T-bet expression in Tim-3+NK cells 
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was highly correlated with the pattern of IFN-γ production, whereas the 
expression pattern of Eomes was opposite that of T-bet (Figure 23B). 
Altogether, these data suggest that repeated stimulation of NK cells by MHC 
class I-deficient tumours induces the functional exhaustion of NK cells 
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Figure 18. Percent, number and function of NK cells in MHC class I-
deficient tumours. (A-C) Twelve days after TC-1 WT or H-2Kb,Db KO cell 
implantation, (A) the percent and (B) number of NK cells were analysed in 
the indicated organs. (C) Lymphocytes from the indicated organs were 
restimulated in vitro with anti-NK1.1 or control IgG for 30 minutes, and IFN-
γ production was then evaluated by flow cytometry. The data shown are from 
at least 2 individual experiments with similar results. The data in C were 
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Figure 19. ERK activation kinetics and functional analysis of TC-1 WT 
or H-2Kb,Db tumour-infiltrating NK cells. (A) ERK1/2 phosphorylation 
was detected by western blot analysis after restimulation in vitro with anti-
NK1.1 or control IgG antibody for 30 minutes with TC-1 WT or H-2Kb,Db 
KO implantation (5x105)-infiltrating NK cells at different time points (B) The 
expression of H-2Kb, Db , IFN-γ and Granzyme B on tumour cells or 
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Figure 20. Infiltrating natural killer cells in MHC class I-deficient 
tumours are functionally exhausted. (A) The expression of Tim-3, PD-1 
and IFN-γ on intratumoural NK cells from mice bearing MC38 WT or H-
2Kb,Db KO tumours was measured over time (n=5). Intratumoural NK cells 
were additionally restimulated with anti-NK1.1 for the analysis of IFN-γ. (B-
E) Twelve days after TC-1 H-2Kb,Db KO implantation, infiltrating 
lymphocytes were restimulated in vitro with anti-NK1.1, and the (B) IFN-γ, 
CD107a, granzyme B and perforin production, (C) T bet and Eomes 
expression were determined in Tim-3+PD-1+ or Tim-3-PD-1- natural killer 
cells by flow cytometry. The data in B and C were analysed by a two-tailed 
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Figure 21. Infiltrating natural killer cells in MHC class I-deficient 
tumours are defected in ERK phosphorylation and cytotoxicity. Twelve 
days after TC-1 H-2Kb,Db KO implantation, infiltrating lymphocytes were 
restimulated in vitro with anti-NK1.1, and the (A) ERK phosphorylation were 
determined in Tim-3+PD-1+ or Tim-3-PD-1- natural killer cells by flow 
cytometry. (B) Intratumoural Tim-3+PD-1+ and Tim-3− PD-1− NK cells were 
isolated from TC-1 H-2Kb, Db KO-bearing mice (pooled from 20 mice). They 
were cocultured with 51Cr labelled TC-1 H-2Kb, Db KO cells as target cells. 
The data in A were analysed by a two-tailed unpaired Student’s t test. The 
data in B were analysed by a two-way ANOVA with Bonferroni multiple 
comparison tests *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, n.s.= not 
significant.  
- 50 - 
 
 
Figure 22. The PD-1/PDL1 axis transmits a negative signal on exhausted 
NK cells. (A) The expression level of PDL-1on MC38 H-2Kb, Db KO was 
measured by flow cytometry. (B) MC38 H-2Kb, Db KO tumour cells (1x105) 
were implanted into mice, which were then treated with anti-PD-1 (300 μg) 
or control IgG twice weekly. A depleting antibody (2.43) for CD8+ T cell 
depletion was injected i.p. twice weekly. The data shown are from at least 2 
individual experiments with similar results. The data in B was analysed by 
two-way ANOVA with Bonferroni multiple comparison tests. *P<0.05, 
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Figure 23. HeLa β2m KO cells induce dysfunction of human NK cells. 
(A-B) Tim-3+ or Tim-3- human NK cells cocultured with HeLa β2m KO cells 
for 3 days were restimulated in vitro with human ULBP-2, and IFN-γ and 
granzyme B production and T-bet and Eomes expression were assessed by 
flow cytometry. The data shown are from at least 2 individual experiments 
with similar results. 
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IL-21 reverses the functions of exhausted NK cells 
Given that vaccination with B/Mo/αGC effectively controls the 
growth of MHC class I-deficient tumours in an NK- and NKT cell-dependent 
manner, I hypothesized that the vaccination could revive the otherwise 
defective effector functions of NK cells in mice bearing MHC class I-
deficient tumours (Figure 11). Thus, I investigated whether B/Mo/αGC could 
reverse the exhausted status of NK cells. The frequency of IFN-γ-producing 
NK cells was dramatically increased with B/Mo/αGC vaccination compared 
with B/Mo alone, regardless of the MHC class I expression level in the 
tumours (Figure 24A). The increase in IFN-γ-producing NK cells upon 
B/Mo/αGC vaccination was dependent on NKT cells because Jα281-deficient 
mice failed to demonstrate a similar increase (Figure 24B). NKT cells are 
known to secrete various cytokines, including IFN-γ, IL-4, TNF-α and IL-21 
51, 52. When B/Mo/αGC was injected, I confirmed that the NKT cells produced 
IFN-γ, IL4, TNF-α and IL-21 (Figure 25). Therefore, I next sought to 
determine whether NKT cell-produced cytokines were responsible for the 
B/Mo/αGC-mediated recovery of NK cell functions in H-2Kb, Db-deficient 
tumours. Because IL-21 and IFN-γ are well-known stimulators of NK cell 
functions 30, 53, I first tested whether these cytokines could revive the effector 
functions of exhausted NK cells in tumours. The addition of IFN-γ partially 
retrieved the IFN-γ-producing capacity of exhausted NK cells, whereas the 
addition of IL-21 completely restored the functions of NK cells isolated from 
H-2Kb, Db-deficient tumours to levels comparable to those of NK cells 
isolated from WT tumours (Figure 26A). I also found that ERK activation in 
NK cells was significantly increased by both IFN-γ and IL-21 in vitro (Figure 
26B). However, the addition of IL-4 or TNF-α did not retrieve the IFN-γ-
producing capacity of exhausted NK cells (Figure 26C). 
To confirm the IFN-γ- and IL-21-dependent reversal of NK cell 
functions in vivo, I administered an anti-IFN-γ-neutralizing Ab or anti-IL-
21R-blocking Ab after B/Mo/αGC vaccination. The B/Mo/αGC-mediated 
recovery of IFN-γ production and CD107a degranulation in Tim-3+PD-1+ NK 
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cells was significantly diminished in mice treated with the anti-IL-21R 
blocking Ab, while partial inhibition was observed in mice treated with the 
anti-IFN-γ Ab (Figure 27). The recovery of T-bet expression in Tim-3+PD-
1+ NK cells following B/Mo/αGC vaccination was also completely abrogated 
by IL-21R blockade (Figure 28A). To address whether alterations in effector 
cytokine production and T-bet expression could lead to changes in the 
cytotoxicity exhibited by each NK cell subset, I tested the cytotoxicity of 
purified Tim-3− PD-1− and Tim-3+PD-1+ NK cells isolated after B/Mo/αGC 
vaccination. I found that B/Mo/αGC vaccination restored the cytotoxic 
functions of Tim-3+PD-1+ NK cells in MHC class I-deficient tumours and that 
IL-21 was required for this process because the IL-21R blockade significantly 
abrogated the recovery of NK cell cytotoxicity (Figure 28B). Consistent with 
these results, the regression of H-2Kb, Db-deficient TC-1 tumour growth 
following B/Mo/αGC vaccination was partially abrogated by IFN-γ 
neutralization, while IL-21R blockade almost completely restored tumour 
progression to the same extent observed in unvaccinated mice (Figure 29A). 
This pattern was reproducible in two different MHC class I-deficient tumour 
models (Figure 29B-C).  
Next, I sought to determine whether IL-21 could directly induce the 
functional recovery of exhausted NK cells in MHC class I-deficient tumours. 
To achieve this goal, I employed Rag1−/− mice to eliminate the effects of IL-
21 on T cells. When I intratumourally injected recombinant IL-21 (rIL-21) 
into MC38 H-2Kb, Db-deficient tumour-bearing Rag 1−/− mice, tumour growth 
was significantly inhibited with an increase in tumour-infiltrating NK cells 
(Figure 30A-B). Although the levels of Tim-3 and PD-1 expression were 
decreased, the expression of IFN-γ and CD107a was increased by 
intratumoural injection of rIL-21 (Figure 30C-D). To establish and isolate 
fully exhausted NK cells, I used an IFN-γ-eYFP-reporter (GREAT) mouse 
system. I isolated Tim-3+PD-1+eYFP− NK cells from MC38 H-2Kb, Db-
deficient tumour-bearing GREAT mice and stimulated them with anti-NK1.1 
in the presence of rIL-21. I observed that IFN-γ secretion of rIL-21-treated 
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Tim-3+PD-1+eYFP− NK cells was significantly increased compared with that 
of vehicle-treated Tim-3+PD-1+eYFP− NK cells (Figure 31A). To analyse the 
direct anti-tumour effects of rIL-21-treated Tim-3+PD-1+eYFP− NK cells, 
these cells were adoptively transferred into IL-2Rγ−/−Rag2−/− mice (lacking B 
cells, T cells and NK cells) bearing MC38 H-2Kb,Db-deficient tumours. I 
observed a significant inhibition of tumour growth in mice that received rIL-
21-treated Tim-3+PD-1+eYFP− NK cells. The growth inhibition in the mice 
that received these cells was slightly higher, although not statistically 
significant, than that in mice that received Tim-3−PD-1− NK cells (Figure 
31B). Collectively, my results suggest that IL-21 could restore the function 
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Figure 24. Exhausted NK cells induced in MHC class I knockout tumour-
bearing mice are reversed by NKT-dependent activation. (A-B) Eleven 
days after TC-1 WT or H-2Kb,Db KO cell implantation, each tumour-bearing 
(A) C57BL/6 or (B) Jα281 KO mouse was vaccinated with B/Mo or 
B/Mo/αGC (1x106). In addition, 12 hours later, lymphocytes from the 
indicated organs were stimulated with control IgG or anti-NK1.1 for 30 
minutes, and IFN-γ production by NK cells was analysed by flow cytometry. 
The data were analysed using a two-tailed unpaired Student’s t test. *P<0.05, 
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Figure 25. NKT cells induce various cytokines in tumour-bearing mice. 
(A) The cytokine profile in the serum of B/Mo/αGC-injected WT, TC-1WT, 
TC-1 H2-KbDb KO or WT&H-2Kb,Db KO mixed tumour-bearing mice at 
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Figure 26. IL-21 mediated functional reversal of exhausted NK cell in 
vitro. Twelve days after TC-1 WT or H-2Kb,Db KO implantation, 
intratumoural lymphocytes were stimulated in vitro with IFN-γ (20 ng/ml) 
and IL-21 (20 ng/ml) alone or in combination and after they were restimulated 
with anti-NK1.1. (A) The IFN-γ production was determined by intracellular 
staining, (B) and ERK phosphorylation was determined by western blot 
analysis. ( (C) Twelve days after TC-1 WT or H-2Kb,Db KO implantation, 
intratumoural lymphocytes were stimulated in vitro with TNF-α (20 ng/ml) 
and IL-4 (20 ng/ml) and then restimulated with anti-NK1.1. The data were 
analysed using a two-tailed unpaired Student’s t test. *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001. 
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Figure 27. IL-21-dependent functional (IFN-γ secretion and CD107a 
degranulation) reversal of Tim-3+ PD-1+ natural killer cells in vivo.  Nine 
days after TC-1 H-2Kb,Db KO implantation, anti-IFN-γ (500 μg/mouse) or 
anti-IL-21R (300 μg/mouse) or both were injected via i.p. and two days later, 
B/Mo/αGC (1x106 cells/mouse) was injected along with the neutralizing 
antibodies. In addition, 12 hours later, infiltrating lymphocyte were 
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Figure 28. IL-21-dependent functional (T-bet expression and cytotoxicity) 
reversal of Tim-3+ PD-1+ natural killer cells in vivo. Nine days after TC-1 
H-2Kb,Db KO implantation, anti-IFN-γ (500 μg/mouse) or anti-IL-21R (300 
μg/mouse) or both were injected via i.p. and two days later, B/Mo/αGC 
(1x106 cells/mouse) was injected along with the neutralizing antibodies. In 
addition, 12 hours later, (A-B) infiltrating lymphocyte were restimulated in 
vitro with anti-NK1.1 and (A) T-bet expression were assessed by flow 
cytometry. (B) Infiltrating Tim-3+PD-1+ and Tim-3-PD-1- natural killer cell 
were isolated in TC-1 H-2Kb,Db KO bearing mice (pooled from 20 mice). 
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Figure 29. Figure 15. IL-21-dependent functional reversal (anti-tumour 
effects) of exhausted Tim-3+ PD-1+ natural killer cells.  (A-C) 
Subcutaneous growth of TC-1 (A), MC38 (B) and CT26 (C) WT and MHC 
Class I KO tumour cells in each mice (n=6) treat with B/Mo(1x106), 
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Figure 30. Intratumoural injection of IL-21 induces functional reversal 
of exhausted Tim-3+ PD-1+ NK cells in Rag− /− mice. (A-E) MC38 WT- or 
H-2Kb,Db KO-bearing Rag 1−/− mice (n=5) were treated with IL-21 (10 
μg/mouse) by intratumoural injection every 3 days from days 9 to 15. (A) 
Tumour growth was measured using a metric calliper 2-3 times per week. (B) 
The number of NK cells was analysed as (= % of CD45.2 NKp46 cells x No.of tumor infiltrating lymphocyte
𝑇𝑢𝑚𝑜𝑟 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑔)
). 
(C-D) Tumour-infiltrating lymphocytes were restimulated using anti-NK1.1, 
and (C) the expression of Tim-3 and PD-1 and (D-E) the production of IFN-
γ and CD107a were analysed in the indicated cell populations.  
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Figure 31. IL-21 directly induce functional reversal of fully exhausted 
Tim-3+ PD-1+ natural killer cells in GREAT mice in vivo.  
(A) IFN-γ-eYFP-reporter (GREAT) mice were implanted with MC38 H-
2Kb,Db KO tumour cells and intratumoural Tim-3+ PD-1+eYFP− NK cells 
were sorted and incubated overnight in the presence or absence IL-21 (20 
ng/ml) with anti-NK1.1 stimulation last 5 h. IFN-γ secretion was analysed by 
flow cytometry. (B) Tumour growth in IL-2Rγ−/−Rag2−/− mice that received 
the indicated group of cells (1 × 105) (n = 10). MC38 H-2Kb, Db-deficient 
tumour cells (5× 104) were inoculated 1 day before NK cell transfer. 
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IL-21 mediated mechanism of reversal of exhausted NK cells 
To further explore the underlying signalling mechanisms of IL-21-
mediated functional reversal of exhausted Tim-3+PD-1+ NK cells, I examined 
the ERK/MAPK, PI3K-AKT and STAT pathways because IL-21 has been 
suggested to be transduced via these signalling pathways 30. I found that IL-
21 induced ERK, AKT, STAT1 and STAT3 phosphorylation (Figure 26B, 
32A, 32C and 32E). When exhausted Tim-3+PD-1+ NK cells were pretreated 
with various signalling inhibitors, IFN-γ secretion and T-bet upregulation by 
IL-21 were reduced in a dose-dependent manner by Fludarabine (STAT1 
inhibitor) and LY294002 (PI3K inhibitor) (Figure 32B, 32F and 32G). 
However, PD98059 (ERK inhibitor) and S31-201 (STAT3 inhibitor) did not 
reduce IFN-γ secretion (data not shown, Figure 32D). I also analysed the 
Foxo1 and T-bet transcription factors. The PI3K-AKT pathway is known to 
enhance proliferation 41 and upregulate T-bet via Foxo1 phosphorylation 42. 
The Foxo1 transcription factor negatively regulates the effector functions of 
NK cells by inhibiting T-bet expression 54. I found that intratumoural rIL-21 
treatment elicited Foxo1 phosphorylation and T-bet upregulation in NK cells 
(Figure 33A). I also confirmed that the addition of exogenous rIL-21 induced 
Foxo1 phosphorylation in exhausted human NK cells (Figure 33B). 
Collectively, these results suggest that STAT1 and the PI3K-AKT-Foxo1 axis 
are crucial regulators of the IL-21-mediated reversal of exhausted Tim-3+PD-
1+ NK cells. 
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Figure 32. STAT1 and the PI3K-AKT pathway are associated with the 
IL-21-mediated functional reversal of Tim-3+PD-1+ NK cells. The 
expression of phospho-STAT1 (A), phospho-STAT3 (C), and phospho-AKT 
(E) on Tim-3+PD-1+ NK cells was analysed after a 1-h incubation with or 
without rIL-21 (20 ng/ml). IFN-γ (B, D and G) and T-bet (F) expression on 
Tim-3+PD-1+ NK cells treated with either vehicle (DMSO) or indicated 
concentrations of Fludarabine (STAT1 inhibitor) (B), S31-201 (STAT3 
inhibitor) (D) or LY294002 (PI3K inhibitor) (F-G) for 30 min, followed by 
overnight incubation in the presence or absence of rIL-21 (20 ng/ml) and 
stimulation with anti-NK1.1.  
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Figure 33. IL-21 elicits Foxo1 phosphorylation and T-bet upregulation in 
mice and humans. (A) Intracellular staining of pFOXO1 and T-bet in Tim-
3+PD-1+ and Tim-3-PD-1- NK cells from MC38 H-2Kb,Db KO-bearing Rag 
1−/− mice that were treated with IL-21 (10 μg/mouse) by intratumoural 
injection every 3 days. (B) Intracellular staining of pFOXO1 and T-bet in the 
indicated NK cells stimulated with IL-21 (50 ng/ml) in vitro for 1 hour. The 
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Reversal of exhausted NK cells in cancer patients by IL-21 
 Recently, PD-1+ and Tim-3+ NK cells were identified in the tumour 
tissues of cancer patients 25, 55, 56. However, the characteristics of these 
intratumoural NK cells in cancer patients have not yet been fully investigated. 
To confirm the presence of Tim-3+PD-1+ NK cells in cancer patients, I 
analysed tumour tissues isolated from patients with different types of cancer. 
When I isolated NK cells from human tumour tissues based on CD16 and 
CD56 coexpression, the expression levels of Tim-3 and PD-1 on 
intratumoural NK cells were much higher than those in normal tissues of the 
same patients (Figure 34A, 34C). MHC class I expression in EpCam+ tumour 
tissues was lower than that in EpCam+ normal tissues (Figure 34B), 
suggesting that Tim-3 and PD-1 expression on intratumoural NK cells was 
presumably induced by MHC class I downregulation in the tumour tissues of 
cancer patients. 
Functional analysis revealed that the effector function of 
intratumoural Tim-3+PD-1+ NK cells was defective as follows: the secretion 
of IFN-γ and granzyme B and the cytotoxicity of the Tim-3+PD-1+ NK cells 
were significantly reduced compared with those of the Tim-3−PD-1− 
counterparts. Intriguingly, however, rIL-21 treatment restored IFN-γ and 
granzyme B secretion and the cytotoxicity of Tim-3+PD-1+ NK cells to levels 
comparable to those of Tim-3−PD-1− NK cells (Figure 35A, 35B and 36). 
Taken together, these results suggest that the functional exhaustion of Tim-
3+PD-1+ NK cells in the tumour tissues of cancer patients can be restored by 
exogenous IL-21 treatment. 
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Figure 34. Expression level of Tim-3 and PD-1 on intratumoural NK cells 
in cancer patients (A) The expression of EpCam and CD45 in the primary 
tumour tissues or normal tissues was analysed by flow cytometry. 
Intratumoural NK cells were isolated by gradient centrifugation, followed by 
depletion of lineage (EpCam, CD3, CD19, CD14)+ cells. (B) HLA-ABC 
expression on gated EpCam+ tumour or normal tissues from cancer patients. 
(C) Tim-3 and PD-1 expression on gated CD16+CD56+ intratumoural NK 
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Figure 35. Rescue of exhausted Tim-3+ PD-1+ NK cells by IL-21 in cancer 
patients. (A) Isolated Tim-3+PD-1+ or Tim-3−PD-1− NK cells were incubated 
overnight in the presence or absence of rIL-21 (20 ng/ml) and stimulated with 
anti-hNKp46 for 5 h. The IFN-γ and granzyme B expression on the indicated 
cells is depicted. (B) Isolated Tim-3+PD-1+ or Tim-3−PD-1− NK cells were 
incubated overnight in the presence or absence of rIL-21 (20 ng/ml) and were 
cocultured with 51Cr-labeled K562 cells as target cells. The data were 
analysed by a two-tailed unpaired Student’s t test *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001. The data are cumulative from five (normal 
tissue) or seven (tumour tissue) independent experiments. All values 
represent the mean ± s.e.m. 
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Figure 36. In vitro cytotoxicity of intratumoural NK cells from cancer 
patients. Isolated Tim-3+PD-1+ or Tim-3−PD-1− NK cells were incubated 
overnight in the presence or absence of rIL-21 (20 ng/ml) and cocultured with 
51Cr-labeled K562 cells as target cells. The data were analysed by two-way 
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Discussion 
To date, MHC class I downregulation or deficiency has been reported 
in the tumour microenvironment of patients with various advanced cancers 2, 
9, 11. The tolerogenic tumour microenvironment induced by MHC class I 
insufficiency in tumour cells is one of the major impediments to effective 
cancer immunotherapy due to the restriction of the cytotoxicity of T 
lymphocytes and the induction of NK cell dysfunction 5. Thus, it remains an 
unsolved question whether the concomitant activation of both adaptive and 
innate immune responses by immunotherapies is sufficient to overcome the 
tolerogenic tumour microenvironment found in advanced cancers containing 
MHC class I-deficient cells. Here, I demonstrate that both the induction of 
adaptive immune responses and the reversal of NK cell exhaustion are critical 
for the treatment of late-stage cancers. 
Previous studies have demonstrated that the activation of NK cells is 
regulated by the integration of signals derived from activation and inhibitory 
receptors expressed on their surface 6. For example, triggering inhibitory 
receptors on NK cells by the ligation of MHC class I expressed on target cells 
interferes with cytotoxicity-promoting signals from activating receptors, 
resulting in the inhibition of target cell lysis by NK cells 7. In contrast, the 
downregulation of MHC class I on target cells releases NK cells from 
inhibitory signals to induce target cell lysis 8. Paradoxically, MHC class I 
deficiency in advanced human cancers has been associated with NK cell 
hyporesponsiveness, which suggests that MHC class I-deficient tumour cells 
have evolved to escape immunosurveillance by NK cells through previously 
unrecognized effects on NK cells 4, 5, 9, 25. In this regard, my findings provide 
direct evidence to explain why NK cells in cancer patients are unable to kill 
MHC class I-deficient or low-expressing tumour cells.  
Tim-3 and PD-1 have recently emerged as specific markers for T cell 
exhaustion during chronic viral infection and cancer progression 13, 14. 
Although the functional exhaustion of NK cells has also been demonstrated 
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in both tumour-bearing mice and cancer patients, cell surface markers that 
can identify exhausted NK cells in the cancer microenvironment remain 
unclear 24, 55. Here, I found that the co-inhibitory receptors Tim-3 and PD-1 
marked functionally defective cells among tumour-infiltrating NK cells in 
mice and humans alike and that tumour cells, especially MHC class I-
deficient tumour cells, directly induced Tim-3+PD-1+ NK cells. I 
hypothesized that perhaps, similar to T cell studies in which multiple rounds 
of TCR stimulation induce PD-1 in chronic viral infection, chronic interaction 
with MHC class I-deficient tumours induces these markers on NK cells. In 
addition, the degranulation, cytokine secretion and cytotoxicity of Tim-3+PD-
1+ NK cells were more defective than those of Tim-3−PD-1− NK cells. My 
study also showed that the expression levels of Tim-3 and PD-1 on 
intratumoural NK cells from patients with different types of cancer were 
much higher than those in normal tissues of the same patients. I also found 
that the expression of Tim-3 and PD-1 on intratumoural NK cells was 
inversely correlated with MHC class I expression in the tissues of cancer 
patients. Although previous studies have demonstrated that PD-1 and Tim-3 
expression on NK cells from cytomegalovirus-infected or cancer patients 
transmits negative signals on NK cell cytotoxicity 22, 24, 25, 55, a few unknown 
features remain to be elucidated regarding the induction of the functional 
exhaustion of NK cells, including (i) whether the ligation of PD-1/PD-L1 or 
Tim-3/galactin-9 on NK cells is required for the induction of NK cell 
exhaustion, (ii) the molecular mechanism by which NK cell exhaustion is 
induced by tumour cells and (iii) the molecular mechanisms involved in the 
upregulation of PD-1 and Tim-3 on NK cells. For example, it has been 
demonstrated that Tim-3 or PD-1 ligation on T cells inhibits TCR stimulation-
dependent signalling pathways and promotes exhaustion of CD8+ T cells 
through the induction of NFAT 57. Therefore, further studies are needed to 
identify the precise mechanism by which PD-1 and Tim-3 signalling 
influence the dysfunction of NK cells and to address which molecular 
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machineries are involved in the induction of NK cell exhaustion during cancer 
progression. 
Previous studies have demonstrated that the production of IFN-γ by 
NK cells increases in a STAT1-dependent manner 58, 59, whereas the 
cytotoxicity of NK cells is abrogated through the STAT3 pathway 60, 
suggesting that STAT1 and STAT3 can oppose each other in the regulation 
of NK cells. In addition, the MAPK/ERK and PI3K/AKT pathways are 
important for promoting cytokine secretion and proliferation by NK cells 61, 
62. My results suggest that IL-21 treatment induces STAT1, STAT3, ERK and 
AKT phosphorylation. However, the functional reversal of exhausted NK 
cells appears to be mediated by STAT1 and the PI3K-AKT-Foxo1 pathway. 
These two mechanisms may act synergistically to promote the functional 
reversal of NK cell exhaustion.  
Prior studies have demonstrated that neo-antigens or various antigens 
targeted by cancer immunotherapeutic vaccines are important for inducing 
anti-tumour effects 63, 64, 65 and that combination therapy (checkpoint 
blockade, cancer vaccines, cytokines and antibodies) with the induction of 
adaptive and innate immune responses could eradicate large established 
tumours in experimental mice 66. In agreement with these findings, my data 
suggest that the spontaneous downregulation of MHC class I on tumour cells 
contributes to tumour evasion from immunosurveillance; to our knowledge, 
these advanced tumours have not previously been curable by a single 
immunotherapy relying on endogenous immune responses, but IL-21 
secretion by NKT cell-activating vaccination or IL-21-mediated NK cell 
therapies effectively eradicate these tumours by reversing NK cell exhaustion. 
I suggest that not only inducing antigen-specific T cell and innate immune 
responses but also restoring NK cell exhaustion via IL-21 signalling are 
crucial for overcoming cancer immuno-evasion. It may be important for 
eliminating heterogeneous tumours containing MHC class I-deficient cells, 
which induce NK cell exhaustion. In addition, the provision of exogenous IL-
21 may expand antigen-specific CD8+ T cells and limit CD8+ T cell 
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exhaustion 32, 33, 34, 40. In this regard, future studies should explore whether our 
vaccine could also restore the exhaustion of CD8+ T cells in tumour 
microenvironments through IL-21 produced by the activated NKT cells. 
 To my knowledge, this is the first report to define Tim-3+PD-1+ NK 
cells as exhausted cells induced by MHC class I-deficient tumours in mice 
and humans. In addition, my study explains how MHC class I-deficient 
tumours escape cancer immunosurveillance, despite their increased 
susceptibility to NK cell-mediated cell cytotoxicity during the initial stage. 
Furthermore, I clearly demonstrated that IL-21 can reverse the functional 
exhaustion of NK cells by activating both the PI3K-AKT-Foxo1 and STAT1 
signalling pathways. Therefore, these findings demonstrate that NK cell 
exhaustion is an attractive drug target for developing anticancer 
immunotherapies and show that enhancing the concentration of IL-21 in the 
tumour microenvironment can be highly beneficial for the treatment of 












Figure 37. Cartoon summary of this study: IL-21 mediated reversal of 
exhausted natural killer cell facilitates anti-tumour immunity in MHC 
class I deficient tumours. 
In this study, I showed that MHC class I-deficient tumor cells directly 
induced the functional exhaustion of mouse & human Tim-3+PD-1+ NK cell 
population. Using various in vitro and in vivo systems, I convincingly 
demonstrated that the effector functions of Tim-3+PD-1+ NK cells, such as 
cytokine secretion and cytotoxicity, are significantly reduced compare to 
Tim3−PD-1− counterparts in tumor bearing mice and cancer patients. 
Importantly, I also found that IL-21 could restores the exhausted effector 
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 국문 초록 
암세포는 체내 면역 세포인 T 세포에 의해서 제거될 수 있지만, 
암세포가 성장하고 전이됨에 따라 암세포 표면의 주 조직성 복합체 I 
(MHC class I) 이 감소 혹은 결핍되어 T 세포에 의해 제거되지 
못한다는 것이 알려져 있다. 이러한 MHC class I 이 감소/결핍된 
암세포는 체내의 자연 살해 세포 (NK cell)에 의해서 제거될 수 있다. 
그러나 실제 암환자의 경우, NK cell 이 충분히 존재 함에도 불구하고, 
MHC class I 이 감소/결핍되어 있는 암세포가 제거되지 못하는 것이 
보고 되고 있다. 본 연구는 이미 본 연구실에서 구축한 항암 
면역치료백신인 BVAC 의 항암 면역효과를 분석하던 중, MHC class 
I 이 없는 암세포에의 효능 및 작용 기전을 밝히기 위해 진행되었다.  
MHC class I 이 결핍된 암 세포주를 제작하여 BVAC 의 
항암효과를 확인했을 때, NK cell 에 의해 효과적으로 MHC class I 이 
결핍된 암의 성장을 억제하였다. 이에 본인은 BVAC 에 의해 MHC 
class I 결핍 암 환경에서의 NK cell 의 기능 저하가 회복될 수 있다는 
가설을 세우고 실험을 진행하였다. 첫번째로, MHC class I 결핍 암 
환경에서 NK cell 의 기능저하가 일어나는지 여부를 실험하던 중, 
MHC class I 결핍 암이 직접적으로 Programmed cell Death-1 
(PD-1) 과 T cell immunoglobulin and mucin domain-3 (Tim-
3) 분자를 NK cell 표면에 유도하는 것을 최초로 확인하였다. 
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두번째로, PD-1+ Tim-3+ NK cell 의 기능이 저하되어 있었고, 이런 
기능저하는 BVAC 에 의해 자극되는 자연 살해 T 세포의 IL-
21 분비에 의해 회복되는 것을 확인하였다. 뿐만 아니라 IL-21 의 
직접적인 처리가 PD-1+ Tim-3+ NK cell 의 기능을 회복시키는 
것을 여러 마우스 실험 모델을 통해 확인할 수 있었다. 세번째로, 기능 
회복 기전은 STAT1 과 PI3K-AKT-FOXO1 신호체계를 통해 
이루어지는 것을 밝혔다. 
추가적으로 여러 종류의 암 환자의 암 조직을 얻어 암세포 
표면의 MHC class I 이 정상세포에 비해 저하되어 있는 것과, 
암세포에 침투된 NK cell 표면에 Tim-3 와 PD-1 분자를 발현하는 
것을 확인하였다. 또한 이런 PD-1+ Tim-3+ NK cell 의 기능이 
저하되어 있고, IL-21 에 의해서 기능이 회복된다는 것을 확인하였다. 
따라서 본 연구를 통해 전이/말기 암에서 주로 발생하는 MHC class I 
감소/결핍 암 세포는 IL-21 에 의한 기능 저하된 NK cell 의 기능 
회복을 통해 제거 될 수 있다는 것을 밝힐 수 있었다. 
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